Related Experiment Video

Updated: Aug 16, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Case study: contrasting challenges of insulin pump therapy in a toddler and adolescent with type 1 diabetes

Elizabeth A Doyle Boland1, Amy T Steffen1, William V Tamborlane1,2

  • 1The Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut (Ms Doyle, Ms Steffen, Dr Tamborlane)

The Diabetes Educator
|August 16, 2005
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) pump therapy effectively manages type 1 diabetes in children and adolescents. This approach improves glycemic control and quality of life, with individualized care supporting independence from an early age.

Area of Science:

  • Pediatric endocrinology
  • Diabetes management
  • Medical device technology

Background:

  • Type 1 diabetes (T1D) management in young patients presents unique challenges, including unpredictable food intake and lifestyle interferences.
  • Continuous subcutaneous insulin infusion (CSII) pump therapy offers a potential solution for optimizing glycemic control in pediatric populations.
  • Patient and family perspectives are crucial in motivating and supporting the adoption of advanced diabetes management technologies.

Observation:

  • Case 1: A 4-year-old boy with T1D on CSII achieved an average HbA1c of 6.3%, with cessation of severe hypoglycemia and improved postprandial control.
  • Case 2: A 12-year-old girl with T1D transitioned to CSII at age 13, improving glycemic control and enabling an active lifestyle, with stabilization post-menarche.
  • Both cases demonstrated increasing independence in diabetes management with age and appropriate support.

Findings:

  • CSII therapy is effective in improving glycemic control (average HbA1c 6.3%) and reducing hypoglycemic episodes in young children with T1D.
  • Adolescents with T1D can achieve improved metabolic control and lifestyle flexibility through CSII, even during periods of hormonal fluctuation.
  • Individualized CSII management strategies are key to successful outcomes in both toddlers and adolescents.

Implications:

  • CSII therapy is a viable and effective option for children of all ages with T1D, with no lower age limit identified.
  • Parenting challenges and educational support needs for CSII therapy vary significantly between toddlers and adolescents.
  • Individualized CSII implementation can lead to sustained glycemic control, enhanced quality of life, and early development of independence in young individuals with T1D.
Abstract

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...